Organigram Global Stock
Organigram Global Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- CEO
- James Yamanaka
- Employees
- 1,139
- Market cap
- $186 M
- IPO
- 05/01/2012
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big…
Organigram Global stock: price history
1D
+0.0%
1W
-3.6%
1M
-10.8%
6M
-34.3%
YTD
-42.9%
1Y
-50.4%
2Y
-44.5%
5Y
-88.1%
10Y
-88.6%
Next earnings date
Next earnings date
22/12/2026 (in 66 days)
Volatility around earnings
~5% weaker price swings than usual
Ask the agents about Organigram Global
Analyst assessment of Organigram Global
0
STRONG BUY
2
BUY
2
HOLD
1
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 17/07/2023
Organigram Global stock metrics
P/E
2.05
P/B
0.37
EV/EBITDA
-7.36
RETURN ON EQUITY
21.7%
NET MARGIN
99.8%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
68.8%
FLOAT SHARES
97,033,843
AVG. DAILY VOLUME (30D)
93,756
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Organigram Global stock
What does Organigram Global do?
Organigram Global Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Canada.
The CEO is James Yamanaka, the company employs around 1,139 people.
The IPO was on 05/01/2012; the stock trades on TSX under the ticker OGI.TO.
What do analysts say about Organigram Global stock?
5 analysts rate the stock, the consensus is Buy (as of 17/07/2023).
This is an external assessment, not a statement by Market Jury.
When does Organigram Global report next?
The next earnings date is 22/12/2026.
Around past earnings, price swings were roughly -5% stronger than usual.
Does Organigram Global pay a dividend?
No, Organigram Global currently does not pay a dividend.
Which stocks are comparable to Organigram Global?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Organigram Global stock analyzed?
Clicking "Analyze stock" lets five strategies assess Organigram Global against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.